Brokerages expect Wave Life Sciences Ltd (NASDAQ:WVE) to announce ($1.26) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Wave Life Sciences’ earnings, with estimates ranging from ($1.37) to ($1.12). Wave Life Sciences reported earnings of ($1.09) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 15.6%. The business is expected to report its next earnings report on Monday, March 11th.
According to Zacks, analysts expect that Wave Life Sciences will report full-year earnings of ($4.99) per share for the current financial year, with EPS estimates ranging from ($5.21) to ($4.66). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.88) per share, with EPS estimates ranging from ($5.03) to ($1.13). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Wave Life Sciences.
Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Friday, November 9th. The company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.02). The company had revenue of $4.49 million for the quarter, compared to analyst estimates of $5.36 million. Wave Life Sciences had a negative return on equity of 107.14% and a negative net margin of 1,114.49%.
In other news, VP Chandra Vargeese sold 3,000 shares of the company’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $55.00, for a total value of $165,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Chris Francis sold 11,575 shares of the company’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $56.00, for a total value of $648,200.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,075 shares of company stock worth $2,435,700. Corporate insiders own 44.20% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Redmile Group LLC lifted its stake in Wave Life Sciences by 0.3% during the 2nd quarter. Redmile Group LLC now owns 2,244,507 shares of the company’s stock worth $85,852,000 after acquiring an additional 6,900 shares in the last quarter. Boxer Capital LLC lifted its stake in Wave Life Sciences by 17.8% during the 2nd quarter. Boxer Capital LLC now owns 1,590,600 shares of the company’s stock worth $60,840,000 after acquiring an additional 240,600 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Wave Life Sciences by 11.8% during the 2nd quarter. Janus Henderson Group PLC now owns 1,518,758 shares of the company’s stock worth $58,092,000 after acquiring an additional 160,545 shares in the last quarter. BB Biotech AG lifted its stake in Wave Life Sciences by 21.7% during the 3rd quarter. BB Biotech AG now owns 1,385,002 shares of the company’s stock worth $69,250,000 after acquiring an additional 247,117 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in Wave Life Sciences by 1.1% during the 3rd quarter. BlackRock Inc. now owns 1,214,843 shares of the company’s stock worth $60,742,000 after acquiring an additional 13,188 shares in the last quarter. 83.46% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ WVE traded down $0.61 on Tuesday, reaching $39.06. 65,000 shares of the company were exchanged, compared to its average volume of 162,006. The firm has a market capitalization of $1.27 billion, a P/E ratio of -10.15 and a beta of 1.10. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.11 and a current ratio of 6.11. Wave Life Sciences has a fifty-two week low of $23.07 and a fifty-two week high of $56.00.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Read More: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.